PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it displays a valid OMB control of the cont er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info

3

## **TRANSMITTAL FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission


sond to a collection of information	runess it displays a valid OND control numbe
Application Number	10/749122-Conf. #3280
Filing Date	December 30, 2003
First Named Inventor	Richard L. BOYD
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	0286336.00153US1/NOR-014CP4

	ENCLOSURES (Check all that apply)					
Fee Transr	mittal Form	Drawing(s)		After Allowance Communication to TC		
Fee	Attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences		
Amendmer	nt/Reply			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After	Final	Petition to Convert to a Provisional Application Proprietary Inf		Proprietary Information		
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence		Status Letter		
Extension	of Time Request	Terminal Disclaimer		X Other Enclosure(s) (please Identify below):		
Express At	pandonment Request	Request for Refund Return Receipt Pos		Return Receipt Postcard		
X Supplemental Information Disclosure Statement		CD, Number of CD(s)				
Certified Copy of Priority Document(s)		Landscape Table on	CD			
	issing Parts/ Application	Remarks				
Reply to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name WILMER CUTLER PICKERING HALE AND DORR LLP						
Signature	inature Och Laced Klrv					
Printed name	Ann-Louise Kerner, Ph.D.					
Date	June 22, 2006			33,523		

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on
the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450.
Alexandria, VA 22313-1450.

Dated: June 22, 2006

Signature: Atestance & Diver (Stephanie R. Douglas)



Docket No.: 0286336.00153US1/NOR-014CP4 (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Richard L. BOYD

Confirmation No.:

3280

Application No.:

10/749122

Art Unit:

1645

Filed:

December 30, 2003

Examiner:

Not Yet Assigned

Title:

DISEASE PREVENTION BY REACTIVATION OF THE THYMUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: June 22, 2006

Ann-Louise Kerner, Ph.D. Registration No.: 33,523 Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109 (617) 526-6000 (telephone) (617) 526-5000 (facsimile) JUN 2 6 2006

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/749122-Conf. #3280	
	NFORMATIO	N DIS	SCLOSURE	Filing Date	December 30, 2003	
5	STATEMENT BY APPLICANT			First Named Inventor	Richard L. BOYD	
				Art Unit	1645	
(Use as many sheets as necessary)		Examiner Name	Not Yet Assigned			
Sheet	1	of	1	Attorney Docket Number	0286336.00153US1/NOR-014CP4	

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( # known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-4,049,805	09-20-1977	Strade	
	AB*	US-5,759,551	06-02-1998	Ladd et al.	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵		
	ВА	EP-0882736A1	1	LABORATORIE THERAMEX, S.A.				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Gojo et al., Gene Therapy and Transplantation, (2000), Vol. 69, pp. 1-9.		
	СВ	Ross et al., "Gene Therapy in the United States: A Five-Year Status Report," Human Gene Therapy, 1996, pp. 1781-1790, Vol. 7.		
	CC	Belhadj et al., "Hepatosplenic gamma-delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report of a Series of 21 Patients," Blood, 2003, pp. 4261-4269, Vol. 102.		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.